<?xml version="1.0" encoding="UTF-8"?>
  	<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:video="http://www.google.com/schemas/sitemap-video/1.1"><url>
        <loc>https://www.cancernetwork.com/view/integrating-functional-testing-and-genomic-profiling-to-guide-cancer-treatment</loc><video:video><video:publication_date>2026-10-26</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/46db26f180b463abcca99c9cdb6dfdf2c776ce6e-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Integrating Functional Testing and Genomic Profiling to Guide Cancer Treatment]]></video:title><video:description><![CDATA[At the Big Ten CRC Summit, VK Gadi, MD, PhD, explained why functional drug testing and genomic profiling should be used together in oncology.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6407427608112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/matching-first-line-combinations-to-disease-pace-and-burden</loc><video:video><video:publication_date>2026-10-26</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/b21395857b178acd87de5696d27840d7d4f552d0-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Matching First-Line Combinations to Disease Pace and Burden]]></video:title><video:description><![CDATA[Moshe C. Ornstein, MD, MA, of Cleveland Clinic says clinicians cannot yet predict which patient with advanced renal cell carcinoma (RCC) will respond better to dual immune checkpoint blockade or to immunotherapy plus a tyrosine kinase inhibitor (TKI), in a discussion moderated by Elizabeth R. Plimack, MD, MS, of Fox Chase Cancer Center. ]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6407098267112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/individualizing-treatment-in-multiple-myeloma</loc><video:video><video:publication_date>2026-10-26</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/861929e27d571698cfbaedb08dc72bd6bf0adfb8-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Individualizing Treatment in Multiple Myeloma]]></video:title><video:description><![CDATA[Dr. Saad Usmani and Dr. Shaji Kumar conclude the discussion by considering how the CEPHEUS findings may be applied to individual patients with newly diagnosed multiple myeloma.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6407085926112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/local-therapy-and-tp53-in-a-high-risk-first-line-decision</loc><video:video><video:publication_date>2026-10-26</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/215de075d86f817fc65d871aa96deb9aa1b01f42-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Local Therapy and TP53 in a High-Risk First-Line Decision]]></video:title><video:description><![CDATA[Siddhartha Devarakonda, MD, of Providence Swedish Cancer Institute says he tries not to push patients with asymptomatic brain metastases from epidermal growth factor receptor (EGFR)-mutated advanced non–small cell lung cancer (NSCLC) toward local therapy, calling whole brain radiation the wrong step for this patient and noting that another consultation costs the patient time.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405195671112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/pfs-mrd-and-treatment-duration-in-multiple-myeloma</loc><video:video><video:publication_date>2026-10-26</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/861929e27d571698cfbaedb08dc72bd6bf0adfb8-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[PFS, MRD, and Treatment Duration in Multiple Myeloma]]></video:title><video:description><![CDATA[Dr. Saad Usmani and Dr. Shaji Kumar discuss how sustained MRD negativity and long-term progression-free survival may inform future treatment strategies for patients with newly diagnosed multiple myeloma.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6407085534112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/case-1-brain-metastases-and-tp53-co-mutation</loc><video:video><video:publication_date>2026-10-26</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/215de075d86f817fc65d871aa96deb9aa1b01f42-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Case 1, Brain Metastases and TP53 Co-Mutation]]></video:title><video:description><![CDATA[Estelamari Rodriguez, MD, MPH, of Sylvester Comprehensive Cancer Center presents a 68-year-old woman with newly diagnosed metastatic lung adenocarcinoma, an epidermal growth factor receptor (EGFR) exon 19 deletion with a concurrent TP53 co-mutation, multiple small asymptomatic brain metastases on staging magnetic resonance imaging, disease confined to lung and brain, and good performance status with support at home.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405198022112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/selecting-first-line-therapy-in-advanced-rcc</loc><video:video><video:publication_date>2026-10-26</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/b21395857b178acd87de5696d27840d7d4f552d0-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Selecting First-Line Therapy in Advanced RCC]]></video:title><video:description><![CDATA[Elizabeth R. Plimack, MD, MS, of Fox Chase Cancer Center opens this CancerNetwork Training Academy discussion on first-line treatment decisions in advanced renal cell carcinoma (RCC) with Terence W. Friedlander, MD, of UCSF Helen Diller Family Comprehensive Cancer Center, and Moshe C. Ornstein, MD, MA, of Cleveland Clinic. ]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6407100440112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/what-pope-leo-xiv-s-lung-cancer-diagnosis-could-mean-for-stigma-nihilism</loc><video:video><video:publication_date>2026-10-22</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/922ba9a18d856dea0c51bca4c895a5cb45acc1a1-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[What Pope Leo XIV’s Lung Cancer Diagnosis Could Mean for Stigma, Nihilism]]></video:title><video:description><![CDATA[Pope Leo XIV’s lung adenocarcinoma diagnosis may increase awareness and combat stigma surrounding lung cancer screening.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6406969182112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/zipalertinib-may-introduce-another-option-to-egfr-exon-20-nsclc</loc><video:video><video:publication_date>2026-10-22</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/41da92df32a82e159c83e0e1e8be4d81b95a32f7-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Zipalertinib May Introduce Another Option to EGFR Exon 20+ NSCLC]]></video:title><video:description><![CDATA[Helena A. Yu, MD, discusses the background of REZILIENT3 and her key takeaways on zipalertinib in EGFR exon 20-mutated NSCLC.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6407147018112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/efficacy-interpretation-quality-of-life-and-dosing-flexibility-with-belantamab-mafodotin</loc><video:video><video:publication_date>2026-10-22</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/627864ea167ec133de98c6d9e9840ec4ee33b0f0-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Efficacy Interpretation, Quality of Life, and Dosing Flexibility With Belantamab Mafodotin]]></video:title><video:description><![CDATA[The faculty turn to the safety and practical aspects of using belantamab mafodotin, drawing on earlier experience with the drug. They discuss how lines of therapy are defined and whether the definition needs refinement, and how efficacy endpoints translate into clinical relevance. Health-related quality of life is reviewed, with the view that good disease control is a driver of better quality of life. The panel describes holding the drug for eye symptoms, restarting at a lower dose, and adjusting dosing frequency to keep responding patients on therapy. They also note the overall response rate and MRD negativity in the study and discuss their interpretation of the data.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6406700716112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/first-6-weeks-post-transplant-maintenance-and-co-mutations</loc><video:video><video:publication_date>2026-10-21</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/1a2a03afd454f318c637036bd15889e30b3fd563-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[First 6 Weeks, Post-Transplant Maintenance, and Co-Mutations]]></video:title><video:description><![CDATA[The panelists describe the first 6 weeks for this patient, including twice-weekly labs, weekly EKGs early on, and which checks can be done locally vs at the academic center.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6406865257112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/impact-of-baseline-comorbidities-on-treatment-decisions</loc><video:video><video:publication_date>2026-10-21</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/5d85b183a65b796025d1b612fee5278201cf7a5c-774x432.png</video:thumbnail_loc><video:title><![CDATA[Impact of Baseline Comorbidities on Treatment Decisions]]></video:title><video:description><![CDATA[The moderator asks whether any of the patient’s baseline comorbidities from the clinical scenario in the previous episode are a concern.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6406778425112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/rash-dose-modifications-and-conclusions-at-extended-follow-up</loc><video:video><video:publication_date>2026-10-21</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/f262d25b087baecf6f9a841774228a3a1b8dd385-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Rash, Dose Modifications, and Conclusions at Extended Follow-Up]]></video:title><video:description><![CDATA[Luis E. Raez, MD, of Miami Cancer Institute, reports that with extended COPERNICUS follow-up, rash in the first 4 months of subcutaneous amivantamab plus lazertinib was lower than in MARIPOSA, similar across age groups, and less often grade 2 or higher, with lower cumulative incidence by 1 year.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405488563112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/extended-copernicus-follow-up-on-skin-toxicity-and-thrombosis</loc><video:video><video:publication_date>2026-10-21</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/f262d25b087baecf6f9a841774228a3a1b8dd385-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Extended COPERNICUS Follow-Up on Skin Toxicity and Thrombosis]]></video:title><video:description><![CDATA[Wade T. Iams, MD, of Tennessee Oncology, presents extended COPERNICUS follow-up: 274 US participants have received subcutaneous amivantamab plus lazertinib, and 214 enrolled at least 4 months before the data cutoff.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405488054112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/monitoring-and-treatment-selection-for-a-community-patient</loc><video:video><video:publication_date>2026-10-21</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/5d85b183a65b796025d1b612fee5278201cf7a5c-774x432.png</video:thumbnail_loc><video:title><![CDATA[Monitoring and Treatment Selection for a Community Patient]]></video:title><video:description><![CDATA[One panelist addresses neuropathy in a patient who has received bortezomib, describing a symptom-driven approach.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6406779886112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/clinical-scenario-for-choosing-a-menin-inhibitor-for-relapsed-npm1-mutated-aml</loc><video:video><video:publication_date>2026-10-21</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/1a2a03afd454f318c637036bd15889e30b3fd563-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Clinical Scenario for Choosing a Menin Inhibitor for Relapsed NPM1-Mutated AML]]></video:title><video:description><![CDATA[The moderator presents Clinical Scenario 1, the panelists then proceed to discuss how various factors that have been brought up in earlier episodes within this program impact their decisions for the patient in this clinical scenario.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6406865529112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/why-ai-needs-a-human-in-the-loop-for-lung-cancer-screening-decisions</loc><video:video><video:publication_date>2026-10-21</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/47fedfea5c70441ce8065140ef8671de017768e4-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Why AI Needs a Human in the Loop for Lung Cancer Screening Decisions]]></video:title><video:description><![CDATA[Training AI on data without good representation of underserved populations may unintentionally widen disparities in lung cancer care.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6406969118112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/treating-the-thyroid-as-an-organ-at-risk-in-supraclavicular-breast-irradiation</loc><video:video><video:publication_date>2026-10-20</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/78fe60709d357838035fe9f4e818c5be252abefc-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Treating the Thyroid as an Organ at Risk in Supraclavicular Breast Irradiation]]></video:title><video:description><![CDATA[Nikolai Strusberg, MD, discussed other toxicities of proton vs photon breast radiation therapy, practice implications, and next steps in capsular contracture research.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6406863599112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/how-clinical-hypothyroidism-was-defined-in-a-proton-vs-photon-breast-rt-study</loc><video:video><video:publication_date>2026-10-20</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/8f5432429a78ffe0f67798d2d3f0e002e674c174-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[How Clinical Hypothyroidism Was Defined in a Proton vs Photon Breast RT Study]]></video:title><video:description><![CDATA[Nikolai Strusberg, MD, explained the clinical hypothyroidism endpoint and how thyroid dose should guide proton vs photon choice in breast cancer.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6406863795112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/depth-and-durability-of-response-in-multiple-myeloma</loc><video:video><video:publication_date>2026-10-19</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/861929e27d571698cfbaedb08dc72bd6bf0adfb8-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Depth and Durability of Response in Multiple Myeloma]]></video:title><video:description><![CDATA[Dr. Saad Usmani and Dr. Shaji Kumar examine the CEPHEUS findings on response depth and durability in newly diagnosed multiple myeloma, with particular emphasis on MRD negativity and its potential implications for treatment duration. ]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6407083971112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/cepheus-design-and-the-role-of-mrd-in-multiple-myeloma</loc><video:video><video:publication_date>2026-10-19</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/861929e27d571698cfbaedb08dc72bd6bf0adfb8-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[CEPHEUS Design and the Role of MRD in Multiple Myeloma]]></video:title><video:description><![CDATA[Dr. Saad Usmani reviews the design of the phase 3 CEPHEUS study in patients with transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma, highlighting the importance of patient fitness and age in defining the study population. ]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6407084677112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/neoadjuvant-radiotherapy-challenges-the-surgery-first-paradigm-in-breast-cancer</loc><video:video><video:publication_date>2026-10-19</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/10227b6490abf7cabcb7a8d62c6e65af56575e06-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Neoadjuvant Radiotherapy Challenges the Surgery-First Paradigm in Breast Cancer]]></video:title><video:description><![CDATA[Leah Katz, MD, MPH, discussesed NeoORB data on neoadjuvant radiotherapy and why radiation timing may open new treatment paradigms in breast cancer.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6406850824112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/co-management-rems-changes-and-what-s-next-for-car-t-in-multiple-myeloma</loc><video:video><video:publication_date>2026-10-19</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/e6ef2497c163c9b6e1faef6b39a480182a6b9b4b-1042x586.png</video:thumbnail_loc><video:title><![CDATA[Co-Management, REMS Changes, and What’s Next for CAR T in Multiple Myeloma]]></video:title><video:description><![CDATA[Asked about the biggest misconception community providers hold about the referral process, Matthew J. Frigault, MD, clinical director of the Cellular Immunotherapy Program at Mass General Brigham Cancer Institute, emphasized that CAR T-cell therapy is a co-management strategy.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6406917517112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/building-a-community-academic-partnership-for-car-t-cell-therapy-in-myeloma</loc><video:video><video:publication_date>2026-10-19</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/e6ef2497c163c9b6e1faef6b39a480182a6b9b4b-1042x586.png</video:thumbnail_loc><video:title><![CDATA[Building a Community-Academic Partnership for CAR T-Cell Therapy in Myeloma]]></video:title><video:description><![CDATA[Matthew J. Frigault, MD, clinical director of the Cellular Immunotherapy Program at Mass General Brigham Cancer Institute, asked what practical steps referring oncologists can take and what an ideal interaction with an academic medical center looks like.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6406918014112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/earlier-referral-enables-outpatient-care-in-multiple-myeloma</loc><video:video><video:publication_date>2026-10-19</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/e6ef2497c163c9b6e1faef6b39a480182a6b9b4b-1042x586.png</video:thumbnail_loc><video:title><![CDATA[Earlier Referral Enables Outpatient Care in Multiple Myeloma]]></video:title><video:description><![CDATA[Adam D. Cohen, MD, director of Myeloma Immunotherapy and professor of medicine at the Hospital of the University of Pennsylvania, asked whether patients lose the chance to receive CAR T-cell therapy if referral comes too late.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6406919750112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/updated-cartitude-2-data-support-earlier-cilta-cel-use-in-multiple-myeloma</loc><video:video><video:publication_date>2026-10-19</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/e6ef2497c163c9b6e1faef6b39a480182a6b9b4b-1042x586.png</video:thumbnail_loc><video:title><![CDATA[Updated CARTITUDE-2 Data Support Earlier Cilta-Cel Use in Multiple Myeloma]]></video:title><video:description><![CDATA[Adam D. Cohen, MD, reviews 5-year data from cohort A of CARTITUDE-2 for cilta-cel and how bridging therapy may lower the risk of late neurotoxicity.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6406918774112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/acquired-resistance-mechanisms-after-first-line-therapy</loc><video:video><video:publication_date>2026-10-19</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/215de075d86f817fc65d871aa96deb9aa1b01f42-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Acquired Resistance Mechanisms After First-Line Therapy]]></video:title><video:description><![CDATA[Estelamari Rodriguez, MD, MPH, of Sylvester Comprehensive Cancer Center presents long-term resistance data from the phase 3 MARIPOSA study in epidermal growth factor receptor (EGFR)-mutated advanced non–small cell lung cancer (NSCLC), where amivantamab plus lazertinib reduced acquired MET amplification approximately fourfold and secondary EGFR resistance mutations approximately fivefold compared with osimertinib.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405197431112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/sequencing-car-t-cell-therapy-and-bispecifics-to-preserve-t-cell-fitness</loc><video:video><video:publication_date>2026-10-19</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/e6ef2497c163c9b6e1faef6b39a480182a6b9b4b-1042x586.png</video:thumbnail_loc><video:title><![CDATA[Sequencing CAR T-Cell Therapy and Bispecifics to Preserve T-Cell Fitness]]></video:title><video:description><![CDATA[With both CAR T-cell therapy and bispecific antibodies now available in early relapse, Adam D. Cohen, MD, director of Myeloma Immunotherapy and professor of medicine at the Hospital of the University of Pennsylvania, asked how clinicians should decide which modality comes first.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6406918296112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/nccn-guidelines-position-car-t-cells-in-early-relapsed-multiple-myeloma</loc><video:video><video:publication_date>2026-10-19</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/e6ef2497c163c9b6e1faef6b39a480182a6b9b4b-1042x586.png</video:thumbnail_loc><video:title><![CDATA[NCCN Guidelines Position CAR T Cells in Early Relapsed Multiple Myeloma]]></video:title><video:description><![CDATA[Matthew J. Frigault, MD, and Adam D. Cohen, MD, outline how updated NCCN guidelines position CAR T-cell therapy in early relapsed multiple myeloma.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6406919850112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/subcutaneous-amivantamab-in-everyday-practice</loc><video:video><video:publication_date>2026-10-19</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/215de075d86f817fc65d871aa96deb9aa1b01f42-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Subcutaneous Amivantamab in Everyday Practice]]></video:title><video:description><![CDATA[Siddhartha Devarakonda, MD, of Providence Swedish Cancer Institute says he sees no remaining role for intravenous amivantamab in epidermal growth factor receptor (EGFR)-mutated advanced non–small cell lung cancer (NSCLC), with subcutaneous administration taking 10 to 15 minutes and easing chair time and scheduling.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405198514112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/monitoring-late-car-t-toxicities-and-treating-high-risk-myeloma-earlier</loc><video:video><video:publication_date>2026-10-19</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/e6ef2497c163c9b6e1faef6b39a480182a6b9b4b-1042x586.png</video:thumbnail_loc><video:title><![CDATA[Monitoring Late CAR T Toxicities and Treating High-Risk Myeloma Earlier]]></video:title><video:description><![CDATA[Matthew J. Frigault, MD, clinical director of the Cellular Immunotherapy Program at Mass General Brigham Cancer Institute, explained that some toxicities of CAR T-cell therapy emerge within the first 30 days, while others can appear 90 days or later after infusion.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6406917324112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/targit-b-iort-boost-blunts-distant-relapse-in-young-patients-with-breast-cancer</loc><video:video><video:publication_date>2026-10-18</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/ef884c1a9c53d2176a4f8108ae28c89323428d67-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[TARGIT-B IORT Boost Blunts Distant Relapse in Young Patients With Breast Cancer]]></video:title><video:description><![CDATA[Leah Katz, MD, MPH, explained how an intraoperative tumor bed boost in TARGIT-B may reduce distant relapse in young patients with breast cancer.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6406850535112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/meaning-centered-therapy-psychiatry-referrals-and-humanistic-cancer-care</loc><video:video><video:publication_date>2026-10-18</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/3ac4d9ec1f49545a568d0725c44e7248d7d1cd01-1280x720.png</video:thumbnail_loc><video:title><![CDATA[Meaning-Centered Therapy, Psychiatry Referrals, and Humanistic Cancer Care]]></video:title><video:description><![CDATA[Erik Bengtsen, MD, discussed meaning-centered therapy at the bedside, framing psychiatry referrals, and a more humanistic approach to care.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6406769312112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/targeting-cyclin-e1-kras-and-dna-repair-beyond-parp-in-ovarian-cancer</loc><video:video><video:publication_date>2026-10-18</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/6451100b19ae9cd04e9945d51e3b030f95117e7b-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Targeting Cyclin E1, KRAS, and DNA Repair Beyond PARP in Ovarian Cancer]]></video:title><video:description><![CDATA[Ursula A. Matulonis, MD, surveyed the exploitable genetic changes driving the next wave of ovarian cancer trials, from CDK2 and WEE1 inhibitors to PARG inhibitors.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6406971905112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/why-keynote-b96-succeeded-where-single-agent-pembrolizumab-did-not</loc><video:video><video:publication_date>2026-10-17</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/999ff441bf1dd1557e87fe96b4c01cfac189076e-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Why KEYNOTE-B96 Succeeded Where Single-Agent Pembrolizumab Did Not]]></video:title><video:description><![CDATA[Ursula A. Matulonis, MD, broke down the trial design, backbone regimen, and preclinical rationale that she believes made KEYNOTE-B96 a positive study.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6406972399112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/radiation-omission-in-favorable-breast-cancer-hinges-on-endocrine-adherence</loc><video:video><video:publication_date>2026-10-17</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/bf2b62007f239eeffceca270cee0653f9e2aface-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Radiation Omission in Favorable Breast Cancer Hinges on Endocrine Adherence]]></video:title><video:description><![CDATA[Leah Katz, MD, MPH, discusses long-term IDEA trial data on omitting radiation and why endocrine therapy tolerance matters in this decision.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6406850825112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/how-psycho-oncology-addresses-existential-distress-body-image-and-intimacy</loc><video:video><video:publication_date>2026-10-17</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/3ac4d9ec1f49545a568d0725c44e7248d7d1cd01-1280x720.png</video:thumbnail_loc><video:title><![CDATA[How Psycho-Oncology Addresses Existential Distress, Body Image, and Intimacy]]></video:title><video:description><![CDATA[Erik Bengtsen, MD, described what sets psycho-oncology apart and how clinicians can open conversations on body image and sexual health.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6406768933112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/addressing-prospective-data-gaps-for-radiotherapy-use-in-multiple-myeloma</loc><video:video><video:publication_date>2026-10-16</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/3814f5d401f4b976aa5b7eb98cfecc86e3a9d985-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Addressing Prospective Data Gaps for Radiotherapy Use in Multiple Myeloma]]></video:title><video:description><![CDATA[Alexandra Dreyfuss, MD, MS, explains why CAR T and bispecific populations are her priority for prospective radiotherapy studies in multiple myeloma.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6406848543112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/how-andrew-pecora-md-is-using-ai-to-help-physicians-fix-the-cost-crisis-in-cancer-care</loc><video:video><video:publication_date>2026-10-16</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/f4e574acd0088e85fb2d04f2fb1ec8336c4439d8-1280x720.png</video:thumbnail_loc><video:title><![CDATA[How Andrew Pecora, MD, Is Using AI to Help Physicians Fix the Cost Crisis in Cancer Care]]></video:title><video:description><![CDATA[Dr. Andrew Pecora on leading the first IV oncolytic virus trial, building a top-50 cancer center, and using AI to fix the cost of cancer care.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6406881984112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/building-an-outpatient-bispecific-step-up-dosing-program-in-community-practice</loc><video:video><video:publication_date>2026-10-16</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/0f49efd25fd14f56bc2890199a443c25a5388e77-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Building an Outpatient Bispecific Step-Up Dosing Program in Community Practice]]></video:title><video:description><![CDATA[Ralph V. Boccia, MD, FACP, explained how community practices can build the workflow and capacity to deliver bispecific step-up dosing in an outpatient setting.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6406548548112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/bridging-logistics-and-closing-takeaways</loc><video:video><video:publication_date>2026-10-16</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/cce3ca0db6b78145397ec35ede82b90cd456b9f3-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Bridging Logistics and Closing Takeaways]]></video:title><video:description><![CDATA[The faculty define holding and bridging therapy, discuss how they coordinate it with the referring practice, and walk through the timeline.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6406967743112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/shared-monitoring-and-a-clinical-scenario</loc><video:video><video:publication_date>2026-10-16</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/cce3ca0db6b78145397ec35ede82b90cd456b9f3-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Shared Monitoring and a Clinical Scenario]]></video:title><video:description><![CDATA[A panelist describes how the treating center, local oncologist, patient, and caregivers share responsibility for monitoring after CAR T-cell therapy, including warning symptoms, immune monitoring, and infection prevention.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6406965430112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/consent-conversations-and-discussion-of-bridging-therapy</loc><video:video><video:publication_date>2026-10-16</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/cce3ca0db6b78145397ec35ede82b90cd456b9f3-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Consent Conversations and Discussion of Bridging Therapy]]></video:title><video:description><![CDATA[One panelist describes the consent conversation with patients and caregivers, including how the treatment works, what to expect from outcomes, the practical process, and side effects such as cytokine release syndrome, ICANS, cranial nerve palsy, colitis, and movement disorders.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6406966015112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/discussion-surrounding-bcma-targeted-options</loc><video:video><video:publication_date>2026-10-16</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/cce3ca0db6b78145397ec35ede82b90cd456b9f3-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Discussion Surrounding BCMA-Targeted Options]]></video:title><video:description><![CDATA[The faculty discuss a recent exchange in Nature Reviews Clinical Oncology on the role of CAR T-cell therapy and where it fits in the treatment sequence, including concerns about toxicity and how recognition and management of these toxicities have evolved.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6406963668112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/guideline-recommendations-and-comparing-car-t-cell-therapy-with-transplant</loc><video:video><video:publication_date>2026-10-16</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/cce3ca0db6b78145397ec35ede82b90cd456b9f3-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Guideline Recommendations and Comparing CAR T-Cell Therapy With Transplant]]></video:title><video:description><![CDATA[The moderator reviews a guideline recommendation on CAR T-cell therapy and T-cell engagers at first relapse, and one panelist describes how it compares with their practice, including the rationale for sequencing and the questions that remain open.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6406965339112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/patient-selection-for-car-t-cell-therapy-at-first-relapse</loc><video:video><video:publication_date>2026-10-16</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/cce3ca0db6b78145397ec35ede82b90cd456b9f3-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Patient Selection for CAR T-Cell Therapy at First Relapse]]></video:title><video:description><![CDATA[Panelists discuss which patients at first relapse make them think of CAR T-cell therapy and which make them pause, including disease burden and the role of holding and bridging therapy, age and fitness, kidney function, and caregiver availability.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6406963777112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/discussion-surrounding-the-definition-of-cure-in-multiple-myeloma</loc><video:video><video:publication_date>2026-10-16</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/cce3ca0db6b78145397ec35ede82b90cd456b9f3-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Discussion Surrounding the Definition of Cure in Multiple Myeloma]]></video:title><video:description><![CDATA[The faculty consider how they would answer a patient who is 5 years out from a single infusion in sustained MRD-negative remission and asks whether they are cured.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6406965636112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/how-to-work-with-a-patient-who-decline-cancer-treatment</loc><video:video><video:publication_date>2026-10-16</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/3ac4d9ec1f49545a568d0725c44e7248d7d1cd01-1280x720.png</video:thumbnail_loc><video:title><![CDATA[How to Work With a Patient Who Declines Cancer Treatment]]></video:title><video:description><![CDATA[Erik Bengtsen, MD, explained how antidepressants may improve quality of life and how he typically works with patients who decline favorable treatment.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6406768738112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/mrd-negativity-with-tec-dara-and-tal-dara-and-its-impact-on-multiple-myeloma-outcomes</loc><video:video><video:publication_date>2026-10-15</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/bb23c10ea4cf1082c7e07770b17e4b14280984bc-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[MRD Negativity With Tec-Dara and Tal-Dara and Its Impact on Multiple Myeloma Outcomes]]></video:title><video:description><![CDATA[Ralph V. Boccia, MD, FACP, compared MRD data with Tec-Dara and Tal-Dara and explained how sustained MRD negativity is reshaping myeloma care.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6406549319112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/sequencing-car-t-cell-therapy-with-radiation-in-high-risk-multiple-myeloma</loc><video:video><video:publication_date>2026-10-15</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/a7e4746ec2a6f454ac07eb16ce31f0126979d984-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Sequencing CAR T-Cell Therapy With Radiation in High-Risk Multiple Myeloma]]></video:title><video:description><![CDATA[Alexandra Dreyfuss, MD, MS, weighs bridging vs consolidative radiotherapy strategies around CAR T-cell infusion in myeloma.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6406848843112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/screening-for-depression-and-starting-antidepressants-in-oncology-care</loc><video:video><video:publication_date>2026-10-15</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/3ac4d9ec1f49545a568d0725c44e7248d7d1cd01-1280x720.png</video:thumbnail_loc><video:title><![CDATA[Screening for Depression and Starting Antidepressants in Oncology Care]]></video:title><video:description><![CDATA[Erik Bengtsen, MD, shares a key depression screening question and explains when oncologists can start a low-dose antidepressant.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6406768737112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/dreamm-7-eligibility-criteria-and-the-enrolled-population-vs-the-approved-indication</loc><video:video><video:publication_date>2026-10-15</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/627864ea167ec133de98c6d9e9840ec4ee33b0f0-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[DREAMM-7 Eligibility Criteria and the Enrolled Population vs the Approved Indication]]></video:title><video:description><![CDATA[The faculty discuss the DREAMM-7 eligibility and exclusion criteria, including the exclusion of patients refractory to daratumumab or bortezomib. They consider how well the trial population reflects patients seen in practice, given limited prior anti-CD38 exposure. The conversation then turns to the enrolled population vs the approved indication of at least 2 prior lines, which was based on a subgroup. Finally, the faculty share their views on that restriction and discuss the survival benefit seen in the study.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6406700922112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/acid-reducers-drug-drug-interactions-and-setting-expectations-for-response</loc><video:video><video:publication_date>2026-10-14</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/1a2a03afd454f318c637036bd15889e30b3fd563-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Acid Reducers, Drug-Drug Interactions, and Setting Expectations for Response]]></video:title><video:description><![CDATA[Explore how menin inhibitors are managed in leukemia care, including key drug interactions, dosing adjustments, and realistic response timelines for patients.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6406865345112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/differentiation-syndrome-cardiac-monitoring-and-administration-of-menin-inhibitors</loc><video:video><video:publication_date>2026-10-14</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/1a2a03afd454f318c637036bd15889e30b3fd563-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Differentiation Syndrome, Cardiac Monitoring, and Administration of Menin Inhibitors]]></video:title><video:description><![CDATA[Learn how clinicians recognize and manage drug-related differentiation syndrome, QTc prolongation, and dosing considerations when starting revimumab or ziftomainib in practice.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6406865528112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/the-promise-of-cervino-majestec-3-and-excaliber-rrmm-in-multiple-myeloma</loc><video:video><video:publication_date>2026-10-14</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/2955f1ccfb43640990d72cf76fce26bb42b8192b-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[The Promise of CERVINO, MajesTEC-3, and EXCALIBER-RRMM in Multiple Myeloma]]></video:title><video:description><![CDATA[Al-Ola A. Abdallah, MD, highlights the data on etentamig, teclistamab/daratumumab, and iberdomide he found most impactful at IMS 2026.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6406711761112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/fixed-duration-bispecific-therapy-for-deep-sustained-responses-in-multiple-myeloma</loc><video:video><video:publication_date>2026-10-14</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/8777f236f8ca03d1eba0f3c1d824f9047c12ce3c-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Fixed-Duration Bispecific Therapy for Deep, Sustained Responses in Multiple Myeloma]]></video:title><video:description><![CDATA[Ralph V. Boccia, MD, FACP, discussed stopping therapy in patients with deep, sustained responses and the move toward fixed-duration multiple myeloma care.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6406548547112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/what-early-copernicus-safety-data-mean-for-practice</loc><video:video><video:publication_date>2026-10-14</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/f262d25b087baecf6f9a841774228a3a1b8dd385-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[What Early COPERNICUS Safety Data Mean for Practice]]></video:title><video:description><![CDATA[Luis E. Raez, MD, of Miami Cancer Institute, summarizes the early COPERNICUS conclusions: enhanced prophylaxis with subcutaneous amivantamab plus lazertinib led to low rates of severe rash, thrombosis, and infusion reactions, though shorter follow-up limits inference.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405489438112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/reading-a-changed-eye-examination-and-impact-on-therapy</loc><video:video><video:publication_date>2026-10-14</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/5d85b183a65b796025d1b612fee5278201cf7a5c-774x432.png</video:thumbnail_loc><video:title><![CDATA[Reading a Changed Eye Examination and Impact on Therapy]]></video:title><video:description><![CDATA[Experts explain how myeloma regimens manage eye toxicity with baseline exams, dose holds, reductions, and longer belantamab dosing intervals to improve safety.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6406780182112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/operationalizing-the-first-dose-and-building-the-oncology-and-eye-care-partnership</loc><video:video><video:publication_date>2026-10-14</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/5d85b183a65b796025d1b612fee5278201cf7a5c-774x432.png</video:thumbnail_loc><video:title><![CDATA[Operationalizing the First Dose and Building the Oncology and Eye Care Partnership]]></video:title><video:description><![CDATA[Practical guidance for starting belantamab: confirm eligibility, coordinate ophthalmology exams, manage reversible eye toxicity with dose holds, and educate patients for confident dosing.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6406779305112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/weighing-cross-trial-safety-comparisons-and-treatment-holds</loc><video:video><video:publication_date>2026-10-14</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/f262d25b087baecf6f9a841774228a3a1b8dd385-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Weighing Cross-Trial Safety Comparisons and Treatment Holds]]></video:title><video:description><![CDATA[Luis E. Raez, MD, of Miami Cancer Institute, and Wade T. Iams, MD, of Tennessee Oncology, consider how to interpret descriptive comparisons between COPERNICUS and MARIPOSA, given median follow-up of 4.9 vs 22 months and no formal statistical testing.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405488055112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/teclistamab-vs-talquetamab-after-relapse-on-car-t-cell-therapy-in-multiple-myeloma</loc><video:video><video:publication_date>2026-10-13</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/ce565c992dddd96ccfb28f3855f016d41abfaec7-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Teclistamab Vs Talquetamab After Relapse on CAR T-Cell Therapy in Multiple Myeloma]]></video:title><video:description><![CDATA[Ralph V. Boccia, MD, FACP, discussed how time since CAR T-cell therapy and toxicity profiles guide bispecific selection in relapsed multiple myeloma.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6406550515112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/how-might-imid-holding-therapy-impact-outcomes-in-r-r-multiple-myeloma-</loc><video:video><video:publication_date>2026-10-13</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/f7d72c49cf8c082f4e1b24039b3783227ba9d389-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[How Might IMiD Holding Therapy Impact Outcomes in R/R Multiple Myeloma?]]></video:title><video:description><![CDATA[Al-Ola A. Abdallah, MD, explains a possible biological reason IMiD holding therapy benefited ide-cel but not cilta-cel recipients.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6406713918112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/why-car-t-cell-therapy-before-bispecifics-may-be-the-ideal-multiple-myeloma-sequence</loc><video:video><video:publication_date>2026-10-12</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/2123343abc68f3c522d372451fe1a91b9e7a3955-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Why CAR T-Cell Therapy Before Bispecifics May Be the Ideal Multiple Myeloma Sequence]]></video:title><video:description><![CDATA[Ralph V. Boccia, MD, FACP, explained why CAR T-cell therapy followed by bispecific antibodies may be the preferred sequence at first relapse in multiple myeloma.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6406548456112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/copernicus-safety-data-and-pragmatic-trial-design</loc><video:video><video:publication_date>2026-10-12</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/215de075d86f817fc65d871aa96deb9aa1b01f42-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[COPERNICUS Safety Data and Pragmatic Trial Design]]></video:title><video:description><![CDATA[Estelamari Rodriguez, MD, MPH, of Sylvester Comprehensive Cancer Center describes COPERNICUS, a pragmatic study of first-line subcutaneous amivantamab plus lazertinib with protocol-directed supportive care in epidermal growth factor receptor (EGFR)-mutated advanced non–small cell lung cancer (NSCLC), which was open at her own site.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405198313112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/tp53-co-mutation-and-first-line-regimen-selection</loc><video:video><video:publication_date>2026-10-12</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/215de075d86f817fc65d871aa96deb9aa1b01f42-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[TP53 Co-Mutation and First-Line Regimen Selection]]></video:title><video:description><![CDATA[Matthew Gumbleton, MD, PhD, of Huntsman Cancer Institute rejects the idea that a TP53 co-mutation points toward chemotherapy in epidermal growth factor receptor (EGFR)-mutated advanced non–small cell lung cancer (NSCLC).]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405196953112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/larger-prostates-showed-post-radiotherapy-urinary-symptom-normalization</loc><video:video><video:publication_date>2026-10-09</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/5af592353ad710d026c1636a0a523c535b1213f7-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Larger Prostates Showed Post-Radiotherapy Urinary Symptom Normalization ]]></video:title><video:description><![CDATA[Allen Khodab, MD discussed how patients with larger prostates had reduced IPSS scores that normalized to the same level as those with normal-sized glands.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6406492207112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/ramantamig-achieves-impressive-rates-of-mrd-negativity-in-rrmm</loc><video:video><video:publication_date>2026-10-09</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/4d82000a96aa61aa10a06300183ea409938d25dc-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Ramantamig Achieves “Impressive” Rates of MRD Negativity in RRMM]]></video:title><video:description><![CDATA[Jeffrey V. Matous, MD, explains why ramantamig’s MRD negativity rates are clinically significant in relapsed/refractory myeloma.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6406431372112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/how-to-navigate-ramantamig-s-low-grade-toxicities-in-multiple-myeloma</loc><video:video><video:publication_date>2026-10-08</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/73e516a152d585762295aa34ac2f7799a65bc365-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[How to Navigate Ramantamig’s Low-Grade Toxicities in Multiple Myeloma]]></video:title><video:description><![CDATA[Jeffrey V. Matous, MD, discusses how to counsel patients on chronic, low-grade toxicities to support adherence to ramantamig.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6406432945112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/case-based-frontline-decisions-in-her2-mutant-nsclc</loc><video:video><video:publication_date>2026-10-08</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/767eb7ff2e49c2ee2198847a60b02456e347745a-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Case-Based Frontline Decisions in HER2-Mutant NSCLC]]></video:title><video:description><![CDATA[This episode applies the discussion to two patients with HER2-mutant non–small cell lung cancer.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405441293112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/clinical-scenarios-and-biomarker-driven-treatment-selection-in-hr-her2-mbc</loc><video:video><video:publication_date>2026-10-08</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/896dcfc5c9d747d7a3dbc3f2c5b5dfd59836f951-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Clinical Scenarios and Biomarker-Driven Treatment Selection in HR+/HER2− mBC]]></video:title><video:description><![CDATA[The panel applies the treatment framework to clinical scenarios involving patients with hormone receptor-positive, HER2-negative metastatic breast cancer (HR+/HER2− mBC) after progression on first-line CDK4/6 inhibitor plus endocrine therapy.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6404818372112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/random-start-protocols-allow-fertility-preservation-without-delaying-treatment</loc><video:video><video:publication_date>2026-10-08</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/c766e547f7a3f757b43e5b55450d9fb80d6bb9c9-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Random-Start Protocols Allow Fertility Preservation Without Delaying Treatment]]></video:title><video:description><![CDATA[Melody Rasouli, MD, MBA, FACOG, explained how random-start ovarian stimulation and rapid sperm banking fit fertility preservation into cancer care.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6406039672112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/monitoring-and-toxicity-management-in-hr-her2-mbc</loc><video:video><video:publication_date>2026-10-08</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/896dcfc5c9d747d7a3dbc3f2c5b5dfd59836f951-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Monitoring and Toxicity Management in HR+/HER2− mBC]]></video:title><video:description><![CDATA[The panel focuses on multidisciplinary monitoring and proactive toxicity management for patients with hormone receptor-positive, HER2-negative metastatic breast cancer (HR+/HER2− mBC), particularly as treatment moves into later-line targeted therapy.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6404817113112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/early-treatment-support-and-real-world-care-gaps</loc><video:video><video:publication_date>2026-10-08</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/767eb7ff2e49c2ee2198847a60b02456e347745a-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Early Treatment Support and Real-World Care Gaps]]></video:title><video:description><![CDATA[This episode maps the early weeks of oral zongertinib and the real-world factors that threaten them.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405442372112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/weighing-safety-vs-persistence-with-car-nk-cell-therapy</loc><video:video><video:publication_date>2026-10-07</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/7f38f421040582f3589ececbc92f5af59a790798-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Weighing Safety vs Persistence With CAR NK Cell Therapy]]></video:title><video:description><![CDATA[Veronika Bachanova, MD, PhD, discussed how the favorable safety profile of CAR natural killer cell therapies may come with trade-offs in persistence and response durability.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6406375262112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/personalized-vaccines-may-have-utility-across-all-lung-cancer-stages</loc><video:video><video:publication_date>2026-10-07</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/ab09d2d8d89f66dc114b5a33c5dbed16c60eb21a-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Personalized Vaccines May Have Utility Across All Lung Cancer Stages]]></video:title><video:description><![CDATA[Dan Costin, MD, discusses where personalized mRNA vaccines could fit into lung cancer care within 5 to 10 years.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6406119900112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/early-copernicus-safety-and-administration-related-reactions</loc><video:video><video:publication_date>2026-10-07</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/f262d25b087baecf6f9a841774228a3a1b8dd385-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Early COPERNICUS Safety and Administration-Related Reactions]]></video:title><video:description><![CDATA[Wade T. Iams, MD, of Tennessee Oncology, reviews early COPERNICUS safety data, in which patients receiving subcutaneous amivantamab plus lazertinib also received intensive skin prophylaxis.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405489736112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/older-more-diverse-patients-enrolled-in-copernicus</loc><video:video><video:publication_date>2026-10-07</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/f262d25b087baecf6f9a841774228a3a1b8dd385-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Older, More Diverse Patients Enrolled in COPERNICUS]]></video:title><video:description><![CDATA[Luis E. Raez, MD, of Miami Cancer Institute, reviews baseline characteristics from the early safety analysis of COPERNICUS, which tested subcutaneous amivantamab plus lazertinib in epidermal growth factor receptor–mutated lung cancer.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405490317112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/clear-ownership-and-ehr-triggers-can-close-gaps-in-oncofertility-referrals</loc><video:video><video:publication_date>2026-10-07</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/0cd3f7d9f7516a528202e5ba752225dc9211794d-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Clear Ownership and EHR Triggers Can Close Gaps in Oncofertility Referrals]]></video:title><video:description><![CDATA[Melody Rasouli, MD, MBA, FACOG, discussed the system breakdowns that delay fertility referrals and how EHR triggers can automate the process.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=undefined</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/hope-and-patient-advocacy-in-relapsed-refractory-multiple-myeloma</loc><video:video><video:publication_date>2026-10-07</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/ee2dcebb52338b07c0f0b1feb3d79bd789bdec59-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Hope and Patient Advocacy in Relapsed/Refractory Multiple Myeloma]]></video:title><video:description><![CDATA[In this closing segment, Elizabeth Bohannon reflects on what continues to give her hope while living with relapsed/refractory multiple myeloma.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6403598302112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/taking-the-first-steps-for-a-personalized-lung-cancer-vaccine-trial</loc><video:video><video:publication_date>2026-10-06</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/e8e7f8835f5c4d82fae608ea8f494d1a8179ac51-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Taking The First Steps for a Personalized Lung Cancer Vaccine Trial]]></video:title><video:description><![CDATA[Dan Costin, MD, describes counseling his first patient on a personalized mRNA vaccine vs observation in the INTerpath-014 trial.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6406121167112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/how-the-big-ten-crc-moves-bench-discoveries-toward-multicenter-trials</loc><video:video><video:publication_date>2026-10-06</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/438ad9b3dee2f9dc61fe279881aff2e76e7142a5-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[How the Big Ten CRC Moves Bench Discoveries Toward Multicenter Trials]]></video:title><video:description><![CDATA[Jan Kitajewski, PhD, discussed how pooled expertise, pilot funding, and investigator support help move bench discoveries toward multicenter trials.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6406257609112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/clinical-scenario-limits-of-endocrine-therapy-and-closing-remarks</loc><video:video><video:publication_date>2026-10-06</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/7899b4dd5458f963c1983b139b4b8ee664948709-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Clinical Scenario: Limits of Endocrine Therapy and Closing Remarks]]></video:title><video:description><![CDATA[Neil Iyengar, MD, presents a second case: a 61-year-old woman with HER2-low metastatic breast cancer who progressed after 22 months on first-line palbociclib and letrozole and 8 months of subsequent endocrine therapy, now with an ESR1 and PIK3CA H1047R co-mutation.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6406257184112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/clinical-scenario-act-on-esr1-emergence-or-wait</loc><video:video><video:publication_date>2026-10-06</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/7899b4dd5458f963c1983b139b4b8ee664948709-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Clinical Scenario: Act on ESR1 Emergence or Wait]]></video:title><video:description><![CDATA[Neil Iyengar, MD, presents a case of a 52-year-old woman with bone-only, hormone receptor-positive, HER2-negative metastatic breast cancer on first-line ribociclib and letrozole who has stable imaging at 12 months but a new ESR1 Y537S mutation on ctDNA with mild bone pain.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6406259430112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/monitoring-camizestrant-safety-in-community-oncology-practice</loc><video:video><video:publication_date>2026-10-06</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/7899b4dd5458f963c1983b139b4b8ee664948709-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Monitoring Camizestrant Safety in Community Oncology Practice]]></video:title><video:description><![CDATA[Carol Tweed, MD, tells community oncologists that camizestrant's cardiac and ocular effects do not require routine referral to cardiology or ophthalmology, calling asymptomatic bradycardia and photopsia a non-issue that does not impair patient function and tends to resolve over time.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6406259044112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/camizestrant-cardiac-and-ocular-safety-in-practice</loc><video:video><video:publication_date>2026-10-06</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/7899b4dd5458f963c1983b139b4b8ee664948709-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Camizestrant Cardiac and Ocular Safety in Practice]]></video:title><video:description><![CDATA[Rebecca Shatsky, MD, reviews the safety profile of camizestrant based on her experience in the CAMBRIA adjuvant trials, highlighting photopsia, brief flashes of light in peripheral vision with no associated eye damage, and bradycardia, which she calls the Apple Watch effect after patients notice low heart rates on wearable devices overnight.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6406258466112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/discussing-a-ctdna-guided-treatment-switch-with-patients</loc><video:video><video:publication_date>2026-10-06</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/7899b4dd5458f963c1983b139b4b8ee664948709-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Discussing a ctDNA-Guided Treatment Switch With Patients]]></video:title><video:description><![CDATA[Rebecca Shatsky, MD, describes telling a patient with a clean scan but a new ESR1 mutation on ctDNA that treatment needs to change, saying she sets that expectation from the start of testing rather than presenting it as a surprise.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6406259137112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/interpreting-pfs-benefit-and-quality-of-life-data-in-serena-6</loc><video:video><video:publication_date>2026-10-06</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/7899b4dd5458f963c1983b139b4b8ee664948709-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Interpreting PFS Benefit and Quality-of-Life Data in SERENA-6]]></video:title><video:description><![CDATA[Carol Tweed, MD, unpacks how to interpret the progression-free survival benefit in the SERENA-6 trial, explaining that a second progression-free survival analysis, counted after patients on the standard arm crossed over to a subsequent therapy, still favored the camizestrant switch group.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6406258852112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/serena-6-trial-design-and-primary-efficacy-data</loc><video:video><video:publication_date>2026-10-06</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/7899b4dd5458f963c1983b139b4b8ee664948709-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[SERENA-6 Trial Design and Primary Efficacy Data]]></video:title><video:description><![CDATA[Rebecca Shatsky, MD, walks through the design of the phase 3 SERENA-6 trial, led by Francois Bedard, who also designed the earlier PADA-1 trial using fulvestrant.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6406258177112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/individualizing-endocrine-therapy-when-resistance-mutations-overlap</loc><video:video><video:publication_date>2026-10-06</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/7899b4dd5458f963c1983b139b4b8ee664948709-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Individualizing Endocrine Therapy When Resistance Mutations Overlap]]></video:title><video:description><![CDATA[Rebecca Shatsky, MD, says her approach to co-mutations depends on the specific patient in front of her, citing a steep drop-off in response across oral selective estrogen receptor degraders that leaves a significant portion of patients without benefit.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6406259816112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/co-mutations-complicate-esr1-directed-treatment-decisions</loc><video:video><video:publication_date>2026-10-06</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/7899b4dd5458f963c1983b139b4b8ee664948709-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Co-Mutations Complicate ESR1-Directed Treatment Decisions]]></video:title><video:description><![CDATA[Carol Tweed, MD, and Neil Iyengar, MD, discuss how co-occurring mutations such as PIK3CA, AKT1, and TP53 complicate treatment decisions once an ESR1 mutation emerges in hormone receptor-positive, HER2-negative metastatic breast cancer.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6406258359112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/oral-serds-and-discussing-ctdna-results-with-patients</loc><video:video><video:publication_date>2026-10-06</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/7899b4dd5458f963c1983b139b4b8ee664948709-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Oral SERDs and Discussing ctDNA Results With Patients]]></video:title><video:description><![CDATA[Rebecca Shatsky, MD, describes discussing ESR1 mutation results with patients, walking them through ctDNA clonal expansion data on a Guardant360 report and explaining why treatment needs to change before disease progresses.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6406256982112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/selinexor-based-quadruplet-targets-myeloma-after-t-cell-redirecting-therapy</loc><video:video><video:publication_date>2026-10-06</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/6e3e75081cc80dc4919ecd564f4c3c34e533e8f1-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Selinexor-Based Quadruplet Targets Myeloma After T-Cell Redirecting Therapy]]></video:title><video:description><![CDATA[Natalie S. Callander, MD, discussed the rationale for combining selinexor, carfilzomib, subcutaneous isatuximab, and dexamethasone in relapsed/refractory myeloma.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6406255430112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/male-oncofertility-content-still-lags-on-nci-cancer-center-websites</loc><video:video><video:publication_date>2026-10-06</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/60a12baec05223e0c724d18e59f4d84b33d58608-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Male Oncofertility Content Still Lags on NCI Cancer Center Websites]]></video:title><video:description><![CDATA[Melody Rasouli, MD, MBA, FACOG, explained why male fertility preservation information trails female content online and how cancer centers can fix it.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6406038216112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/why-high-risk-stage-i-nsclc-needs-a-post-surgical-vaccine-option</loc><video:video><video:publication_date>2026-10-05</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/2ccd046c9f58fef04ec5acd94a98ff48ea68b5ef-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Why High-Risk Stage I NSCLC Needs a Postsurgical Vaccine Option]]></video:title><video:description><![CDATA[Dan Costin, MD, explains the rationale for testing a personalized mRNA vaccine after resection of high-risk stage I NSCLC.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6406121360112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/expanding-car-t-and-bispecific-antibody-research-in-hiv-associated-lymphoma</loc><video:video><video:publication_date>2026-10-05</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/81284df7ef93c1a3e50bf46408946dab8935685c-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Expanding CAR T and Bispecific Antibody Research in HIV-Associated Lymphoma]]></video:title><video:description><![CDATA[Paul Rubinstein, MD, discussed how cooperative groups are expanding CAR T and bispecific antibody research for patients with HIV-associated lymphoma.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6406253639112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/balancing-cure-and-toxicity-in-complex-lung-cancer-radiotherapy-regimens</loc><video:video><video:publication_date>2026-10-05</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/421e3c00e2218f7c0ac702d801e8829085c49481-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Balancing Cure and Toxicity in Complex Lung Cancer Radiotherapy Regimens]]></video:title><video:description><![CDATA[Nitin Ohri, MD, MS, discusses how his team manages toxicity and treatment tolerance as combination regimens grow more complex.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405969868112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/cns-monitoring-and-when-to-defer-local-therapy</loc><video:video><video:publication_date>2026-10-05</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/215de075d86f817fc65d871aa96deb9aa1b01f42-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[CNS Monitoring and When to Defer Local Therapy]]></video:title><video:description><![CDATA[Estelamari Rodriguez, MD, MPH, of Sylvester Comprehensive Cancer Center contrasts central nervous system (CNS) imaging in the phase 3 MARIPOSA and FLAURA2 studies of epidermal growth factor receptor (EGFR)-mutated advanced non–small cell lung cancer (NSCLC), noting that one scanned every patient on a set schedule while the other continued imaging mainly in patients with baseline brain metastases.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405196852112</video:player_loc></video:video></url><url>
        <loc>https://www.cancernetwork.com/view/defining-high-risk-disease-and-outcomes-with-brain-metastases</loc><video:video><video:publication_date>2026-10-05</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/cancernetwork/215de075d86f817fc65d871aa96deb9aa1b01f42-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Defining High-Risk Disease and Outcomes With Brain Metastases]]></video:title><video:description><![CDATA[Siddhartha Devarakonda, MD, of Providence Swedish Cancer Institute pushes back on the high-risk label in epidermal growth factor receptor (EGFR)-mutated advanced non–small cell lung cancer (NSCLC), noting that when 89% of patients with analyzable circulating tumor DNA in the phase 3 MARIPOSA study carry at least 1 high-risk feature, the term loses meaning.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6405198415112</video:player_loc></video:video></url></urlset>